Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Keytruda
Keytruda
Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda
BioSpace
Mon, 10/17/22 - 10:51 am
Kineta
Merck
Keytruda
anti-VISTA
monoclonal antibodies
solid tumors
OncoSec sheds 45% of staff to fund IL-12 drug through Keytruda combo trial
Fierce Biotech
Wed, 10/5/22 - 10:31 am
OncoSec Medical
melanoma
clinical trials
Keytruda
layoffs
Tavo
Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done
Fierce Pharma
Thu, 09/29/22 - 07:42 pm
Merck
Keytruda
cancer
oncology
ESMO
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Fierce Pharma
Thu, 09/15/22 - 11:15 pm
Merck
Keytruda
Bristol Myers Squibb
Opdivo
melanoma
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
Mon, 09/12/22 - 10:57 am
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining
Fierce Pharma
Mon, 09/12/22 - 10:52 am
Merck
Keytruda
head and neck cancer
ESMO
ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda
Fierce Pharma
Thu, 09/8/22 - 04:40 pm
Merck
Keytruda
Astellas
Seagen
Padcev
ESMO
urothelial cancer
ESMO 2022 – the new liver cancer entrants line up
EP Vantage
Thu, 09/8/22 - 10:39 am
ESMO
liver cancer
Keytruda
tislelizumab
camrelizumab
Merck
BeiGene
Novartis
ESMO 2022 – Keytruda secures a renal cancer monopoly
EP Vantage
Thu, 09/8/22 - 12:03 am
Merck
Keytruda
renal cancer
Bristol Myers Squibb
Roche
ESMO
Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again
Fierce Pharma
Wed, 08/3/22 - 09:15 pm
Merck
Keytruda
FDA
liver cancer
Lenvima
Merck Dives As Drug-Pricing Bills Undercut Second-Quarter Profit
Investors Business Daily
Thu, 07/28/22 - 06:37 pm
Merck
earnings
Keytruda
Merck dodged billions in US taxes in offshoring Keytruda profits, Senate Democrats contend
Fierce Pharma
Thu, 07/28/22 - 11:06 am
Merck
Keytruda
taxes
Senate
Seagen, Astellas claim positive results in study key to cancer drug's success
BioPharma Dive
Tue, 07/26/22 - 11:26 am
Seagen
Astellas
Padcev
Merck
Keytruda
bladder cancer
clinical trials
Merck’s Keytruda fails head and neck cancer trial
CNBC
Wed, 07/20/22 - 09:44 am
Merck
Keytruda
head and neck cancer
clinical trials
Merck to support Transgene and BioInvent led oncolytic virus clinical trial
Biopharma Reporter
Tue, 06/28/22 - 05:51 pm
Merck
Keytruda
clinical trials
Transgene
Bioinvent
solid tumors
Merck Predicts Over 80 Potential Oncology Approvals Through 2028
BioSpace
Wed, 06/8/22 - 10:32 am
Merck
oncology
ASCO 2022
Keytruda
#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets
Endpoints
Mon, 06/6/22 - 10:31 am
ASCO 2022
CG Oncology
Merck
Keytruda
EQRx
sugemalimab
ASCO: Merck touts Keytruda's 'convergent' benefits across postsurgery lung cancer patient groups
Fierce Pharma
Mon, 05/30/22 - 10:18 am
ASCO 2022
Merck
Keytruda
lung cancer
The patent winter is coming
EP Vantage
Wed, 05/25/22 - 10:41 am
patents
biosimilars
patent cliff
Keytruda
Opdivo
Eliquis
Darzalex
Revlimid
Humira
Stelara
AbbVie
Merck
Bristol Myers Squibb
JNJ
Could This FDA Approval Be a Boost for Merck?
Motley Fool
Thu, 04/28/22 - 11:04 am
Merck
Keytruda
FDA
endometrial cancer
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »